Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
* *H. pylori* eradication in combination with antibiotics.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be increased as needed. Doses exceeding 40 mg twice daily should be administered with caution.
* ***H. pylori* Eradication:** 40 mg orally twice daily for 7-14 days in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily (or other antibiotic regimens as per local protocol).
## Pediatric Dosing
* **Erosive Esophagitis (ages 5 to 16 years):** 40 mg orally once daily for up to 4 weeks for moderate to severe erosions. Some children may benefit from 20 mg orally once daily.
* Dosing for pediatric patients with pathological hypersecretory conditions is not well-established.
## Dose Adjustments
No dose adjustment is typically necessary for patients with hepatic impairment or mild to moderate renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Use in patients receiving ritonavir.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and arthralgia. Long-term use of PPIs has been associated with increased risk of bone fractures, *Clostridium difficile* infection, hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Atazanavir and Nelfinavir:** Pantoprazole may decrease their absorption due to increased gastric pH.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **Warfarin:** PPIs may increase the INR and risk of bleeding with warfarin.
* **Certain Antiretrovirals (e.g., rilpivirine):** Concomitant use with PPIs is not recommended due to potential for virologic failure.
## Monitoring
* Monitor for clinical improvement of GERD symptoms.
* Monitor for adverse effects, especially with long-term use (e.g., bone fractures, *C. difficile* infection, electrolyte abnormalities).
* Consider magnesium levels in patients on long-term therapy or taking other medications that can cause hypomagnesemia.
## Clinical Pearls
* Pantoprazole is available in oral and intravenous formulations.
* Oral pantoprazole should be taken at least 30 minutes before a meal.
* For patients who have difficulty swallowing, pantoprazole delayed-release tablets can be mixed with applesauce, tomato juice, or pudding; or can be dispersed in 100 mL of water or 100 mL of 5% dextrose solution for administration via nasogastric tube.
* The 20 mg dose is not available as an intravenous formulation.
**Disclaimer:** This information is intended for clinical use and does not substitute for professional medical judgment. Always consult the most current prescribing information and relevant guidelines for complete details.
